SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing ...

Starting sacubitril/valsartan (Entresto) for recently decompensated heart failure with ejection fraction (EF) over 40% improved a key prognostic marker and, for those in the 40-60% range, clinical ...

Start most patients newly diagnosed with heart failure with reduced ejection fraction on the disorder's four foundational drug regimens all at once, all on the day the diagnosis is made, Gregg C.

The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.